Suplatast

DB19138InvestigationalSmall molecule

Suplatast is under investigation in clinical trial NCT05983471 (Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)).

Mechanism: Pharmacologically active on Nuclear factor of activated T-cells, cytoplasmic 1
Curator reviewed
Formula / weight: C₁₆H₂₆NO₄S · 328.45 g/mol (avg)
Also known as: Sulfonium, (3-((4-(3-ethoxy-2-hydroxypropoxy)phenyl)amino)-3-oxopropyl)dimethyl- · Suplatast cation · Suplatast ion

Resolves to

Compound

UNII4T0HO29O56CAS94055-75-1ChEMBLCHEMBL1180156ChEBI32172KEGGC12869

Structure

InChIKeyDYZJXZOQQRXDLE-UHFFFAOYSA-OSMILESCCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1

Targets

O95644NFATC1

What you can answer from here — as of October 01, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Suplatast, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account